Related Experiment Video
Updated: Jun 2, 2026
11:31
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
B cell-directed therapies in type 1 diabetes
Eliana Mariño1, Pablo A Silveira, Jessica Stolp
1Immunology Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Trends in Immunology
|May 3, 2011
Summary
B cell depletion therapies show promise for treating type 1 diabetes (T1D). Studies in non-obese diabetic mice demonstrate prevention and reversal of T1D, offering insights for human clinical trials.
Area of Science:
- Immunology
- Endocrinology
- Diabetes Research
Background:
- B cells contribute to type 1 diabetes (T1D) pathogenesis by presenting antigens and secreting autoantibodies, leading to beta cell destruction.
- This understanding has spurred interest in B cell depletion as a therapeutic strategy for T1D.
Purpose of the Study:
- To review and compare recent studies utilizing distinct B cell-depleting agents in the non-obese diabetic (NOD) mouse model.
- To evaluate the efficacy of these agents in preventing and reversing T1D within the NOD model.
- To discuss the translational potential of findings from animal studies for human T1D clinical trials.
Main Methods:
- Comparative analysis of five recent studies employing different B cell-depleting agents and protocols.
- Evaluation of therapeutic outcomes in the non-obese diabetic (NOD) mouse model of type 1 diabetes.
Main Results:
- Successful prevention and reversal of type 1 diabetes (T1D) were achieved across studies using various B cell-depleting agents in the NOD mouse model.
- Distinct agents and protocols demonstrated efficacy in mitigating T1D progression in this preclinical model.
Conclusions:
- B cell depletion is a viable therapeutic approach for type 1 diabetes (T1D), as evidenced by successful outcomes in the NOD mouse model.
- Insights from preclinical studies can inform the optimization of B cell-depleting therapies, including rituximab, for human clinical application in recent-onset T1D.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...